|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-3-5
|
|
pubmed:abstractText |
Fenfluramine was withdrawn from the U.S. market in 1997 because of its association with cardiac-valve abnormalities in adults. The combination of fenfluramine and phentermine had been widely used to promote weight loss, and many women were inadvertently exposed during the first trimester of pregnancy. The possible effect on the developing fetus has not been studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0040-3709
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
125-30
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11877776-Abnormalities, Drug-Induced,
pubmed-meshheading:11877776-Abortion, Spontaneous,
pubmed-meshheading:11877776-Appetite Depressants,
pubmed-meshheading:11877776-Cohort Studies,
pubmed-meshheading:11877776-Drug Therapy, Combination,
pubmed-meshheading:11877776-Female,
pubmed-meshheading:11877776-Fenfluramine,
pubmed-meshheading:11877776-Humans,
pubmed-meshheading:11877776-Infant, Newborn,
pubmed-meshheading:11877776-Phentermine,
pubmed-meshheading:11877776-Pregnancy,
pubmed-meshheading:11877776-Pregnancy Trimester, First,
pubmed-meshheading:11877776-Prospective Studies
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine.
|
|
pubmed:affiliation |
Department of Pediatrics, Division of Dysmorphology and Teratology, University of California San Diego, La Jolla, CA 92093, USA. klyons@ucsd.edu
|
|
pubmed:publicationType |
Journal Article
|
